DRMA RSI Chart
Last 7 days
1075%
Last 30 days
1358.6%
Last 90 days
819.6%
Trailing 12 Months
72.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 155.4K | 0 | 0 | 247.2K |
2022 | 0 | 0 | 0 | 63.6K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Oct 06, 2022 | bradrick brittany | acquired | - | - | 9,810 | - |
Oct 06, 2022 | scott kathleen d. | acquired | - | - | 11,359 | - |
Oct 06, 2022 | sandler andrew seth | acquired | - | - | 10,120 | - |
Oct 06, 2022 | fisher mary | acquired | - | - | 9,810 | - |
Oct 06, 2022 | wierenga wendell | acquired | - | - | 20,654 | - |
Oct 06, 2022 | hale david f | acquired | - | - | 30,155 | - |
Jul 07, 2022 | sandler andrew seth | acquired | - | - | 8,874 | - |
Jul 07, 2022 | hale david f | acquired | - | - | 26,441 | - |
Jul 07, 2022 | wierenga wendell | acquired | - | - | 18,110 | - |
Jul 07, 2022 | fisher mary | acquired | - | - | 8,602 | - |
Which funds bought or sold DRMA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 1.00 | 1.00 | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | sold off | -100 | -132,980 | - | -% |
May 15, 2024 | ARMISTICE CAPITAL, LLC | reduced | -93.75 | 51.00 | 193 | -% |
May 15, 2024 | BOOTHBAY FUND MANAGEMENT, LLC | unchanged | - | -2,390 | 4,930 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -10.62 | -1,558 | 2,358 | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 8,203 | 8,203 | -% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 6.00 | 6.00 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 7,031 | 7,031 | -% |
May 13, 2024 | UBS Group AG | reduced | -55.71 | -8.00 | 15.00 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | unchanged | - | -2,545 | 4,919 | -% |
Unveiling Dermata Therapeutics, Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Dermata Therapeutics, Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Dermata Therapeutics, Inc News
Income Statement (Quarterly) | |||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q1 | 2022Q4 |
Revenue | 29.7% | 69.00 | 53.00 | 38.00 | - |
Operating Expenses | 44.3% | 3,204 | 2,220 | 2,278 | 1,712 |
S&GA Expenses | -100.0% | - | 1,085 | 1,085 | 822 |
R&D Expenses | 41.0% | 1,601 | 1,135 | 1,193 | 889 |
Interest Expenses | - | - | - | 38.00 | 42.00 |
Income Taxes | - | - | - | - | 150* |
Net Income | -46.9% | -3,134 | -2,133 | -2,240 | -1,669 |
Net Income Margin | -11.5% | -35.15* | -31.53* | -58.33* | -151.18* |
Free Cashflow | -135.7% | -2,704 | -1,147 | -1,649 | -1,825 |
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -35.1% | 5,180 | 7,979 | 7,323 | 8,713 | 9,295 | 6,944 | 8,975 | 11,026 | 9,044 | 11,624 | 13,686 | 1,137 | 871 | 605 | 2,066 |
Current Assets | - | - | - | - | - | - | - | - | - | - | 11,624 | 13,686 | 1,137 | - | 605 | 2,065 |
Cash Equivalents | -36.4% | 4,734 | 7,438 | 6,631 | 8,439 | 8,767 | 6,241 | 8,067 | 10,628 | 8,191 | 10,799 | 12,603 | 427 | 1,330 | 530 | 1,992 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 322* |
Liabilities | -15.5% | 1,372 | 1,624 | 917 | 683 | 1,207 | 923 | 1,504 | 1,366 | 1,191 | 1,517 | 1,195 | 1,643 | 2,713 | 3,783 | 2,276 |
Current Liabilities | - | - | - | - | - | - | - | - | - | - | 1,517 | 1,195 | 1,643 | - | 3,783 | 1,723 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 556 | 731 |
Shareholder's Equity | -40.1% | 3,808 | 6,355 | 6,407 | 8,030 | 8,088 | 6,022 | 7,471 | 9,660 | 7,853 | 10,107 | 12,491 | - | 712 | - | - |
Retained Earnings | -5.9% | -56,522 | -53,387 | -51,253 | -49,534 | -47,833 | -45,593 | -43,923 | -41,499 | -38,768 | -35,982 | -33,429 | -31,716 | - | -28,079 | -24,843 |
Additional Paid-In Capital | 1.0% | 60,329 | 59,743 | 57,660 | 57,564 | 55,921 | 51,615 | 51,393 | 51,158 | 46,620 | 46,089 | 45,919 | 31,203 | - | - | - |
Shares Outstanding | 69.5% | 6,661 | 3,931 | 3,189 | 3,189 | 2,388 | 770 | 756 | 631 | 521 | 521 | 521 | 119 | - | 119 | - |
Float | - | - | - | - | 4,800 | - | - | - | 4,000 | - | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Cashflow From Operations | -135.7% | -2,704 | -1,147 | -1,771 | -1,840 | -1,649 | -1,825 | -2,561 | -1,839 | -2,607 | -1,803 | -2,210 | -903 | -776 | -535 | -1,369 | - | - |
Share Based Compensation | 357.1% | 587 | 128 | 131 | 131 | 131 | 221 | 235 | 262 | 213 | 489 | 143 | 994 | 280 | - | - | - | - |
Cashflow From Financing | -100.0% | - | 1,954 | -35.42 | 1,512 | 4,175 | - | 200* | 4,276 | - | -626* | 14,386 | - | 1,576 | 313 | 1,386 | - | - |
Statements of Operations (unaudited) - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 1,600,741 | $ 1,192,633 |
General and administrative | 1,602,819 | 1,085,049 |
Total operating expenses | 3,203,560 | 2,277,682 |
Loss from operations | (3,203,560) | (2,277,682) |
Other income and expenses: | ||
Interest income, net | 69,298 | 37,540 |
Net loss | $ (3,134,262) | $ (2,240,142) |
Net loss per share of common stock, basic and diluted | $ (0.47) | $ (2.27) |
Weighted-average basic and diluted shares | 6,660,840 | 985,848 |
Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Assets: | ||
Cash and cash equivalents | $ 4,733,681 | $ 7,438,135 |
Prepaid expenses and other current assets | 446,075 | 540,499 |
Total assets | 5,179,756 | 7,978,634 |
Liabilities: | ||
Accounts payable | 822,546 | 866,028 |
Accrued and other current liabilities | 549,220 | 757,588 |
Total liabilities | 1,371,766 | 1,623,616 |
Stockholders' Equity: | ||
Common Stock, par value $0.0001, 250,000,000 shares authorized; 6,660,840 shares issued and outstanding as of March 31, 2024; 3,930,840 shares issued and outstanding as of December 31, 2023, respectively. | 666 | 393 |
Additional paid-in capital | 60,329,464 | 59,742,503 |
Accumulated deficit | (56,522,140) | (53,387,878) |
Total stockholders' equity | 3,807,990 | 6,355,018 |
Total liabilities and stockholders' equity | $ 5,179,756 | $ 7,978,634 |